Press Coverage – Afecta Pharmaceuticals

Dec 19, 2016
CEO/CFO Magazine

Creating New Drugs Based on Safe Existing Compounds Using a Systems Biology Based, Computationally Driven Pharmacometric Platform with Current Programs in Inflammatory Diseases such as Atopic Dermatitis and Psoriasis

Monday, December 19th, 2016, Irvine, CA: “Afecta’s pipeline of new immune-modulators, novel discovery platform and product focused business model fits perfectly into the new paradigm of twenty first century medicine; that is to find ways to develop more effective and personalized drugs to treat patients at lower costs and with shorter timelines. Our previous successes are testament to our ability to achieve that goal.”- Bruce W. Kovacs, MD
Oct 22, 2016
Southern California Biomedical Council

Afecta Pharmaceuticals to Present at the 18th Annual Southern California Biomedical Conference in Long Beach

Saturday, October 22, 2016, Irvine, CA: Afecta Pharmaceuticals, a privately-held, clinical-stage biopharmaceutical company developing novel treatments for women and children, will present at the 18th Annual Southern California Biomedical Conference on November 4th, 2016, at the Long Beach Hilton Hotel.
Mar 13, 2016
American Chemical Society

Afecta Pharmaceuticals to Present at the 2016 American Chemical Society Meeting in San Diego

Friday, March 11, 2016, Irvine, CA: Afecta Pharmaceuticals, a privately-held, clinical-stage biopharmaceutical company developing novel treatments for women and children, will present at the 2016 American Chemical Society meeting on March 15, 2016, at the San Diego Convention Center.